These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 7771665)

  • 1. Blunted growth hormone response is associated with early relapse in alcohol-dependent patients.
    Heinz A; Dettling M; Kuhn S; Dufeu P; Gräf KJ; Kürten I; Rommelspacher H; Schmidt IG
    Alcohol Clin Exp Res; 1995 Feb; 19(1):62-5. PubMed ID: 7771665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced dopaminergic function in alcoholics is related to severe dependence.
    Schmidt LG; Dettling M; Graef KJ; Heinz A; Kuhn S; Podschus J; Rommelspacher H
    Biol Psychiatry; 1996 Feb; 39(3):193-8. PubMed ID: 8837980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alcoholics with reduced dopamine D2 receptor function possess normal platelet monoamine oxidase activity.
    Balldin J; Berggren U; Lindstedt G; Oreland L
    Alcohol Alcohol; 1994 Nov; 29(6):659-61. PubMed ID: 7695780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acquired prolactin deficiency (APD) after treatment for Cushing's disease is a reliable marker of irreversible severe GHD but does not reflect disease status.
    Mukherjee A; Murray RD; Teasdale GM; Shalet SM
    Clin Endocrinol (Oxf); 2004 Apr; 60(4):476-83. PubMed ID: 15049963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levodopa treatment does not affect low-dose apomorphine test in patients with Parkinson's disease.
    Happe S; Tings T; Helmschmied K; Neubert K; Wuttke W; Paulus W; Trenkwalder C
    Mov Disord; 2004 Dec; 19(12):1511-5. PubMed ID: 15390061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of DRD2 and ANKK1 genotypes on apomorphine-induced growth hormone (GH) response in alcohol-dependent patients.
    Lucht M; Samochowiec A; Samochowiec J; Jasiewicz A; Grabe HJ; Geissler I; Rimmbach C; Rosskopf D; Grzywacz A; Wysiecka JP; Tybura P; Brzuchalski B; Bieńkowski P
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Feb; 34(1):45-9. PubMed ID: 19796663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopaminergic responsivity in alcoholism: trait, state, or residual marker?
    Dettling M; Heinz A; Dufeu P; Rommelspacher H; Gräf KJ; Schmidt LG
    Am J Psychiatry; 1995 Sep; 152(9):1317-21. PubMed ID: 7653687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apomorphine-induced growth hormone response is attenuated by ethanol but not dextromethorphan.
    Budde H; Zimmermann US; Steffin B; Rommelspacher H; Schmidt LG; Smolka MN
    Alcohol Clin Exp Res; 2007 Jan; 31(1):100-3. PubMed ID: 17207107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Behavioral responsitivity to dopamine receptor agonists after extensive striatal dopamine lesions during development.
    Neal-Beliveau BS; Joyce JN
    Dev Psychobiol; 1998 May; 32(4):313-26. PubMed ID: 9589220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential influence of D1 and D2 dopamine receptors on acute opiate withdrawal in guinea-pig isolated ileum.
    Capasso A; Sorrentino L
    Br J Pharmacol; 1997 Mar; 120(6):1001-6. PubMed ID: 9134209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The dopamine agonist apomorphine differentially affects cognitive performance in alcohol dependent patients and healthy controls.
    Schellekens AF; van Oosterwijck AW; Ellenbroek B; de Jong CA; Buitelaar JK; Cools L; Verkes RJ
    Eur Neuropsychopharmacol; 2009 Jan; 19(1):68-73. PubMed ID: 18829269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth hormone response to low-dose apomorphine in restless legs syndrome.
    Happe S; Bachmann CG; Helmschmied K; Neubert K; Wuttke W; Paulus W; Trenkwalder C
    Growth Horm IGF Res; 2007 Aug; 17(4):323-7. PubMed ID: 17512770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Entry of extracellular calcium mediates dopamine D1-stimulated growth hormone release from goldfish pituitary cells.
    Wong AO; Van Goor F; Chang JP
    Gen Comp Endocrinol; 1994 Jun; 94(3):316-28. PubMed ID: 7926640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. No association of dopamine receptor sensitivity in vivo with genetic predisposition for alcoholism and DRD2/DRD3 gene polymorphisms in alcohol dependence.
    Wiesbeck GA; Dürsteler-MacFarland KM; Wurst FM; Walter M; Petitjean S; Müller S; Wodarz N; Böning J
    Addict Biol; 2006 Mar; 11(1):72-5. PubMed ID: 16759339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Further neuroendocrine evidence for reduced D2 dopamine receptor function in alcoholism.
    Balldin J; Berggren U; Lindstedt G; Sundkler A
    Drug Alcohol Depend; 1993 Apr; 32(2):159-62. PubMed ID: 8508726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Growth hormone response to the GABA-B agonist baclofen in 3-week abstinent alcoholics.
    Ozsoy S; Esel E; Turan T; Kula M
    Alcohol; 2007 Dec; 41(8):551-6. PubMed ID: 18047908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growth hormone response to apomorphine in obsessive-compulsive disorder.
    Pitchot W; Hansenne M; Moreno AG; Ansseau M
    J Psychiatry Neurosci; 1996 Nov; 21(5):343-5. PubMed ID: 8973055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of allelic association of dopamine D1 and D2 (TaqIA) receptor gene polymorphisms with reduced dopaminergic sensitivity to alcoholism.
    Heinz A; Sander T; Harms H; Finckh U; Kuhn S; Dufeu P; Dettling M; Gräf K; Rolfs A; Rommelspacher H; Schmidt LG
    Alcohol Clin Exp Res; 1996 Sep; 20(6):1109-13. PubMed ID: 8892535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroendocrine evidence for reduced dopamine receptor sensitivity in alcoholism.
    Balldin JI; Berggren UC; Lindstedt G
    Alcohol Clin Exp Res; 1992 Feb; 16(1):71-4. PubMed ID: 1348401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Motor response to a dopamine D3 receptor preferring agonist compared to apomorphine in levodopa-primed 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys.
    Blanchet PJ; Konitsiotis S; Chase TN
    J Pharmacol Exp Ther; 1997 Nov; 283(2):794-9. PubMed ID: 9353400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.